key: cord-0967121-9ovi3lne
authors: Kucukyurt, Selin; Yagiz Ozogul, Yeliz; Ercaliskan, Abdulkadir; Kabasakal, Levent; Eskazan, Ahmet Emre
title: Therapy‐related chronic myeloid leukemia in a patient receiving peptide receptor radionuclide therapy for pancreatic neuroendocrine tumor
date: 2020-09-07
journal: Cancer Rep (Hoboken)
DOI: 10.1002/cnr2.1282
sha: cec54b74a674d158df6b2228e9d55205578a145f
doc_id: 967121
cord_uid: 9ovi3lne

BACKGROUND: Therapy‐related leukemia is a well‐recognized clinical syndrome. Peptide receptor radionuclide therapy (PRRT) is a modern therapeutic approach using radionuclide combined with somatostatin analog peptide for inoperable or metastatic neuroendocrine tumors. AIMS: Hematologic toxicities including late‐onset myeloid neoplasms have been reported after PRRT; however, therapy‐related chronic myeloid leukemia (TR‐CML) following PRRT is a relatively rare entity. METHODS: We present a 64‐year‐old male who received PRRT for pancreas neuroendocrine tumor and then developed TR‐CML 60 months after the initiation of PRRT. The patient responded well to imatinib therapy. RESULTS: Patients with TR‐CML generally have similar tyrosine kinase inhibitor responses and outcomes when compared to de novo cases. CONCLUSIONS: The physicians should be aware of the short‐ and long‐term hematologic toxicities of PRRT including TR‐CML, and careful monitoring is mandatory in this group of patients.

Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm characterized by the overproduction of myeloid cells and the presence of Philadelphia (Ph) chromosome that is characterized by the reciprocal translocation of chromosomes 9 and 22-t(9;22). Risk factors for CML include older age, male gender, and radiation exposure. [1] [2] [3] Therapy-related leukemia (TR-L) is defined as having a prior history of any malignant neoplasm that was treated with chemotherapy and/or radiotherapy prior to the time of diagnosis of leukemia. 4 On the other hand, therapy-related CML (TR-CML) is a relatively rare entity, and approximately, 150 cases of TR-CML or CML as a secondary malignancy have been reported in the literature. [4] [5] [6] [7] TR-L can be associated with certain karyotypes such as abnormalities of chromosomes 5 and/or 7 or a complex karyotype. 5 On the contrary, isolated t(9;22) (q34;q11) abnormalities occur in TR-CML, and additional cytogenetic abnormalities are not usually observed. 6 However, Kantarjian et al 5 have detected monosomy 7 in addition to t (9;22) in a patient who was diagnosed with Ph + CML at 126th month of cytotoxic chemotherapy for primary ovarian cancer.

Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) constitute a heterogenous group of tumors with their origin in neuroendocrine cells, and most commonly, the primary lesion is located in gastric mucosa, intestine, rectum, and pancreas. Peptide receptor radionuclide therapy (PRRT), which is a tumor-targeted strategy that uses radiation to induce tumor cell death in NET via β particleemitting radionuclide radiolabeled to a somatostatin peptide analog. 8 PRRT with 177 Lu-DOTA 0 -Tyr 3 -octreotate ( 177 Lu-DOTATATE) or 90 Y-DOTA 0 -Tyr 3 -octreotide ( 90 Y-DOTATOC) is an effective therapeutic approach in the treatment of inoperable or metastatic GEP-NETs that express somatostatin receptors. 9 Sunitinib is a multitarget tyrosine kinase inhibitor (TKI), which is one of the treatment options in patients with advanced pancreatic neuroendocrine tumors (PNETs). 10 We herein present a case who was first diagnosed with PNET and received sunitinib and PRRT and then developed TR-CML during the follow-up. During the follow-up, the patient had persisting leukocytosis and thrombocytosis, which were thought to be due to postsplenectomy state. The patient was evaluated because of progressive neutrophilic leukocytosis in February 2019. He had no complaints or showed no signs/symptoms of infection. Leukocyte count was 42.1 × 10 9 /L, hemoglobin was 11.7 g/dL, and platelet count was 692 × 10 9 /L. Peripheral blood smear showed granulocytosis with different stages of maturation from myelocyte to neutrophils; 5% myelocytes, 2% metamyelocytes, 6% band cells, 59% neutrophils, 10% basophils, 2% eosinophils, 13% lymphocyte, and 3% monocyte. Peripheral blood and bone marrow aspirate smears at the time of diagnosis are shown in For PNET, the patient continued receiving octreotide until October 2019, and this treatment was discontinued subsequently due to refractory disease. Transarterial chemoembolization was planned, but the patient refused this treatment modality. The timeline of treatment sequence was displayed in Figure 2 .

Then the patient discontinued imatinib for 1.5 months due to nausea and vomiting, and at the 9th month of TKI therapy in December 2019, MMR was lost (BCR-ABL1 IS was 2.54%). We rechallenged imatinib with antiemetics, which was well tolerated.

Molecular response status has not been evaluated yet due to COVID-19 pandemic.

Patients with TR-L are typically at high risk, and their outcomes are inferior than those with the corresponding de novo cases. 5 However, prior to TKI era, the treatment responses were shown to be generally similar in both cases with TR-CML and de novo CML. 4, 6 Similarly, in the TKI era, response to TKI treatment is excellent in patients with TR-CML in chronic phase. 6 Our patient also responded well to TKI treatment, and MMR was achieved at the 6th month of imatinib.

Sunitinib can be associated with multiple toxicities, and cases who developed CML following sunitinib use have been described in the literature. 10 However, these cases have long-term treatment history with sunitinib, unlike our case. Systemic treatment options for advanced GEP-NETs include PRRT. Subacute bone marrow toxicities, which include thrombocytopenia, anemia, leukopenia, and lymphopenia, are the main dose limiting hematologic adverse events of PRRT. Nadir counts commonly occur 4 to 6 weeks and improve within 8 weeks. 12 The most serious long-term toxicity associated with PRRT is irreversible myelotoxicity. Late-onset myeloid neoplasms F I G U R E 1 The peripheral blood and bone marrow aspirate smears of our patient. A, Blood film reveals a blast, lymphocyte, and anisothrombi (Wright -Giemsa×1000) . B, Blood film shows normal-appearing basophil. C, Blood film reveals a myelocyte. D, Blood film shows a metamyelocyte. E, Bone marrow aspirate shows hyperplasia of elements of the granulocytic series, also polychromatophilic normoblasts, and blue sea histiocyte F I G U R E 2 Treatment timeline of our patient (CML, chronic myeloid leukemia; MMR, major molecular response; PNET, pancreatic neuroendocrine tumor; PRRT, peptide receptor radionuclide therapy) have been reported after treatment with PRRT with a mean incidence of 2.6%, 8 however, a few cases of TR-CML following PRRT were reported. 8, [13] [14] [15] Brieau et al 16 This patient was a 61-year-old male with history of prior chemoembolization, and he was Ph + with no additional cytogenetic abnormalities. Our case did not receive any chemotherapy, and he developed TR-CML 60 months after the initiation of PRRT.

Clonal chromosomal abnormalities in the Ph-negative (CCA/Ph−) metaphases after TKI treatment can be observed in patients with CML. 17 In our case, no metaphases were detected initially, and thus, we cannot spaculate whether the tetraploidy was present at the time of CML diagnosis or not. In addition to that, tetraploidy was detected in only one metaphase, and CCAs are generally defined as abnormalities present in ≥2/20 metaphases or if the abnormalities are present in one metaphase in ≥2 assessments. 17 So, since we did not perform another bone marrow cytogenetic evaluation yet, we cannot say this cytogenetic abnormality is clonal, and also we cannot comment on the possible impact of this tetraploidy on the outcome of our patient with a relatively short follow-up period under TKI therapy.

In conclusion, although TR-myeloid neoplasms can be observed in patients receiving PRRT, TR-CML is a rare event following PRRT. TR-AML and TR-MDS patients generally have inferior prognosis than that of de novo cases; on the other hand, patients with TR-CML generally have similar TKI responses and outcomes when compared to de novo patients. Although our patient is an optimal responder to TKI therapy, the follow-up duration is relatively short, thus, we cannot comment on the long-term outcome of the defined case. PRRT is an effective and relatively safe treatment option; however, physicians should be aware of the long-term hematological toxicities of this treatment modality including TR-CML.

We would like to thank our patient for allowing us to share his story.

Letter: a new consistent chromosomal abnormality in chronic myelogemous leukemia identified by quinacrine fluorescence and Giemsa staining

Targeting the BCR-ABL tyrosine kinase in chronic myeloid leukemia

Late effect of atomic bomb radiation on myeloid disorders: leukemia and myelodysplastic syndromes

Therapy-related chronic myeloid leukemia: an epidemiological, clinical and pathogenetic appraisal

Therapy-related leukemia and myelodysplastic syndrome: clinical, cytogenetic, and prognostic features

Incidences and outcomes of therapy-related chronic myeloid leukemia in the era of tyrosine kinase inhibitors: surveillance of the CML cooperative study group

Therapy related chronic myeloid Leukemia (trCML) or non-therapy related second malignancy chronic myeloid Leukemia (smCML) following diffuse large B-cell lymphoma (DLBCL): a case report and review of literature

Assessment of Therapy-Related Myeloid Neoplasms in Patients With Neuroendocrine Tumors After Peptide Receptor Radionuclide Therapy: A Systematic Review

177Lu-DOTATATE therapy in patients with neuroendocrine tumours including high-grade (WHO G3) neuroendocrine tumours: response to treatment and long-term survival update

Sunitinib malate for the treatment of pancreatic neuroendocrine tumors

The impact of BCR-ABL1 transcript type on tyrosine kinase inhibitor responses and outcomes in patients with chronic myeloid leukemia

Long-term efficacy, survival, and safety of [ 177 Lu-DOTA 0 ,Tyr 3 ]octreotate in patients with Gastroenteropancreatic and bronchial neuroendocrine Tumors

Persistent hematologic dysfunction after peptide receptor radionuclide therapy with 177

incidence, course, and predicting factors in patients with Gastroenteropancreatic neuroendocrine Tumors

Prospective observational study of 177 Lu-DOTA-octreotate therapy in 200 patients with advanced metastasized neuroendocrine tumours (NETs): feasibility and impact of a dosimetry-guided study protocol on outcome and toxicity

Safety and outcomes of 177 Lu-DOTATATE for neuroendocrine tumours: experience in New South Wales, Australia

High risk of myelodysplastic syndrome and acute myeloid leukemia after 177Lu-octreotate PRRT in NET patients heavily pretreated with alkylating chemotherapy

Clonal chromosomal abnormalities appearing in Philadelphia chromosome-negative metaphases during CML treatment

Therapy-related chronic myeloid leukemia in a patient receiving peptide receptor radionuclide therapy for pancreatic neuroendocrine tumor

Ahmet Emre Eskazan has received advisory board honorarium from Novartis, and he also received speaker bureau honoraria from Novartis and Bristol-Myers Squibb and Pfizer outside the present study. Other authors have no conflicts of interest to declare.

All authors had full access to the data in the study and take responsi- 

Written informed consent was obtained from the patient prior to publication.

The data that support the findings of this article are available on request from the corresponding author. The data are not publicly available due to privacy and ethical restrictions.